Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia (RECONNECT-S)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01544608
First received: February 20, 2012
Last updated: June 19, 2013
Last verified: June 2013

February 20, 2012
June 19, 2013
July 2012
December 2012   (final data collection date for primary outcome measure)
  • Use of atypical antipsychotic(s) during hospitalisation. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
  • Daily dosage of atypical antipsychotic(s) during hospitalisation. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
  • Mode of administration of atypical antipsychotic(s) during hospitalisation. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
Same as current
Complete list of historical versions of study NCT01544608 on ClinicalTrials.gov Archive Site
  • Percent of patients with atypical antipsychotic as monotherapy. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
  • Percent of patients with combinations of antipsychotics. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
  • Main criteria of an antipsychotic's selection during hospitalisation expressed as percentage. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
  • Use of psychometric scales in day to day practice in therm of evaluation of the disease symptoms and thus efficacy of the treatment. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
  • Description of the usage of concomitant psychiatric medication (other than atypical antipsychotic) during the hospitalization. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
  • Relationship between medication used during the hospitalization and maintenance therapy recommended upon discharge. [ Time Frame: Hospitalisation period, an expected average of 3 weeks (variable per patient). ] [ Designated as safety issue: No ]
    The data will be collected at one visit at the moment of discharge from the hospital.
Same as current
Not Provided
Not Provided
 
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
A Non- Interventional Study to Observe Real Life Usage of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia.

The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose and mode of administration of the medication.

RECONNECT-S BETA

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Psychiatric Institutes

Schizophrenia
Not Provided
Subjects who are hospitalized due to acute psychotic episode.
All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1076
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meet the diagnostic criteria for schizophrenia stated in The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria.
  • Subject is hospitalised due to an acute psychotic episode.
  • Ability of the subject to understand and comply with the requirements of the study, as judged by the investigator.

Exclusion Criteria:

  • Current participation in any clinical trial.
  • Previous enrolment in the present NIS (in case of recurrence occurred during the enrolment period).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Egypt,   Saudi Arabia,   United Arab Emirates
 
NCT01544608
NIS-NME-XXX-2011/1
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Study Chair: Talaat Matar, CONSULTANT PSYCHIATRIST Obaid Alla Hospital,Ras Al Khaima,UAE
Study Chair: Tarek Darwish, CONSULTANT PSYCHIATRIST Sheikh Khalifa Medical City(SKMC), Abudhabi,UAE
Study Chair: Sohail Khan, CONSULTANT PSYCHIATRIST Jeddah Psychiatric hospital,Jeddah, Saudi Arabia
Study Chair: Tarek Okasha, PROFESSOR Ain Shams University, Cairo, Egypt
Study Chair: Mohamed Nasr, PROFESSOR Cairo University, Egypt
AstraZeneca
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP